Cervical cancer, the second leading cause of cancer deaths in women, is the consequence of high-risk human papillomavirus (HPV) infections. Toward the development of therapeutic vaccines that can induce both innate and adaptive mucosal immune responses, we analyzed intravaginal (ivag) vaccine delivery of live attenuated Salmonella enterica serovar Typhimurium expressing HPV16L1 as a model antigen. Innate immune responses were examined in cervicovaginal tissues by determining gene expression patterns by microarray analysis using nylon membranes imprinted with cDNA fragments coding for inflammation-associated genes. At 24 h, a wide range of genes, including those for chemokines and Th1-and Th2-type cytokine and chemokine receptors were up-regulated in mice ivag immunized with Salmonella compared to control mice. However, the majority of transcripts returned to their steady-state levels 1 week after immunization, suggesting a transient inflamma- Cervical cancer is the second leading cause of cancer deaths among women worldwide, with half a million new cases per year, of which 83% occur in developing countries (54). Cervical cancer is caused by infection with a subset of human papillomavirus (HPV), of which type 16 is found most frequently (62). HPV vaccines based on highly purified virus-like particles (VLP) from HPV have been shown to be safe, highly immunogenic, and effective in preventing the development of HPV16 and -18 infections and associated cervical neoplasia (53, 70). However, these prophylactic vaccines can only prevent ca. 70% of all cervical cancers if administered to young adolescents before sexual activity. During the decades necessary to implement prophylactic strategies, millions of women will be or have already been infected by HPVs and may develop associated malignant lesions that could be treated by therapeutic vaccines. Up to now, different therapeutic vaccines, usually targeting the HPV E6 and/or E7 oncogenes and administered parenterally, have shown only limited clinical success (39). Cell-mediated immune responses are important in controlling both HPV infections and HPV-associated neoplasms, as shown by the increased prevalence of these diseases when impaired cell-mediated immunity occurs, such as in transplant recipients or in human immunodeficiency virus-infected patients (38,61,63). The immunosuppressive microenvironment of the cervical mucosa favors the development of high-grade squamous intraepithelial lesions and/or cervical cancer, which correlates with local type II cytokines (24), absence of gamma interferon (IFN-␥) (23), and reduced density and function of Langerhans cells (25), as well as an increased proportion of regulatory T cells in the draining lymph nodes of cervical cancer patients (17, 67). In addition, there is little or no inflammation at the site of primary HPV infection and HPV may be able to suppress the host immune response (35), in particular, type 16, which was recently shown to down-regulate the expression of Toll-like receptor 9 (TLR9) in human primary keratinocy...